Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes

Figures & data

Table 1 Summary of published clinical trials

Study	Subjects	n	Bromocriptine	Duration	Results –change in
			Dosage	(Weeks)	Fasting BG (mg/dL)	HbA1c (%)	Weight
Observational trials
Meier et al^Citation24	OB	33	1.25 mg daily	6	NA	NA	−2.3 kg
	DM2	15	2.5 mg daily	4–8	−99 insulin group −65 oral agent group	NA	−1.1 kg
Kamath et al^Citation23	OB	13	4.8 mg daily	8	no change	NA	NA
Randomized trials
Cincotta et al^Citation20	OB	17	1.6 to 2.4 mg daily	18	no change	NA	−6.3 kg
Pijl et al^Citation21	DM2	22	4.8 mg daily	16	−28	−0.6	no change
Aminorroaya et al^Citation22	DM2	40	2.5 mg daily	12	−27	−0.4	no change
Wasada et al^Citation25	DM2	13	2.5 mg 2 × daily	30	no change	NA	no change

Abbreviations: DM2, type 2 diabetics; OB, obese non-diabetics; HbA_1c, glycosylated hemoglobin; BG, blood glucose; NA, data not available.

Meier AH Cincotta AH Lovell WC Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics Experientia 1992 48 248 253 1547854

 PubMedGoogle Scholar

Kamath V Jones CN Yip JC Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women Diabetes Care 1997 20 1697 1701 9353611

 PubMed Web of Science ®Google Scholar

Cincotta AH Meier AH Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects Diabetes Care 1996 19 667 670 8725871

 PubMed Web of Science ®Google Scholar

Pijl H Ohashi S Matsuda M Bromocriptine: a novel approach to the treatment of type 2 diabetes Diabetes Care 2000 23 1154 1161 10937514

 PubMed Web of Science ®Google Scholar

Aminorroaya A Janghorbani M Ramezani M Haghighi S Amini M Does bromocriptine improve glycemic control of obese type-2 diabetics? Horm Res 2004 62 55 59 15205563

 PubMed Web of Science ®Google Scholar

Wasada T Kawahara R Iwamoto Y Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients Diabetes Care 2000 23 1039 1040 10895875

 PubMed Web of Science ®Google Scholar